Combination drug study for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two targeted drugs, glumetinib and osimertinib, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can help control the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with non-small cell lung cancer (NSCLC) that has spread and cannot be removed by surgery.
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (able to do daily activities without needing help).
- You must not have received treatment with an EGFR inhibitor or MET inhibitor before.
- You must not have cancer that has spread to the lining of the brain or cause symptoms with brain metastases.
- You must be willing to avoid certain medications that could interact with the study drugs.
- If you are of childbearing potential, you must use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
This study tests a new combination of two medicines for people with advanced non-small cell lung cancer that has a specific marker called MET overexpression. The trial hopes to see if adding the new drug (glumetinib) to standard chemotherapy works better than chemotherapy alone.
This trial tests a combination of three targeted drugs for people with advanced non-small cell lung cancer that has a specific EGFR gene change. The goal is to see if the combination can control the cancer when previous treatments have stopped working.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
Hear when a new Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.